PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportssubstance-related disorders
MeSH D019966 - substance-related disorders
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D064419:Chemically-induced disorders
0 Companies
0 Drugs
Success rate
D001523:Mental disorders
0 Companies
0 Drugs
Success rate
D019966: 
Substance-related disorders
$
Success rate
D000075067:Oral substance abuse
0 Companies
0 Drugs
Success rate
D000079524:Narcotic-related disorders
0 Companies
0 Drugs
Success rate
D002189:Marijuana abuse
0 Companies
0 Drugs
Success rate
D009357:Neonatal abstinence syndrome
0 Companies
0 Drugs
Success rate
D010623:Phencyclidine abuse
0 Companies
0 Drugs
Success rate
D011605:Substance-induced psychoses
0 Companies
0 Drugs
Success rate
D013375:Substance withdrawal syndrome
D014029:Tobacco use disorder
$
Success rate
D015819:Intravenous substance abuse
0 Companies
0 Drugs
Success rate
D019969:Amphetamine-related disorders
0 Companies
0 Drugs
Success rate
D019970:Cocaine-related disorders
$
Success rate
D019973:Alcohol-related disorders
$
Success rate
D058545:Inhalant abuse
0 Companies
0 Drugs
Success rate
D000076064:Drug misuse
0 Companies
0 Drugs
Success rate
D000074609:Marijuana use
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Alembic PharmaceuticalsDesipramine Desipramine  2021-07-07   
AllerganDesipramine Desipramine  1987-06-05   
Amneal PharmaceuticalsDesipramine Desipramine  2016-03-17   
ANI PharmaceuticalsDesipramine Desipramine  1987-12-08   
Chartwell PharmaceuticalsDesipramine Desipramine  1988-05-24   
Heritage PharmaceuticalsDesipramine Desipramine  2016-05-05   
Novast LaboratoriesDesipramine Desipramine  2017-12-26   
SanofiDesipramine Pertofrane  1982-01-01   
Validus PharmaceuticalsDesipramine Norpramin  1982-01-01   
Clinical Trials
Historical Success Rate
Phase 1
35%
28/81
Phase 2
45%
28/62
Phase 3
59%
13/22
Approved: 2Overall Success rate: 9%
All Clinical Trials
No data
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use